Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New guidance published yesterday by a team led by NDORMS Associate Professor Jonathan Cook will help researchers recruit the right number of people for clinical trials and answer key research questions.

How do researchers decide how many people they need to recruit into their clinical trials? Until recently, there was surprisingly little practical guidance available to help them. But a team led by NDORMS Associate Professor Jonathan Cook yesterday published new guidance to help researchers decide the sample size needed for their trials and explain their decisions in later academic papers.

The number of people needed in a trial is based on how big a difference the treatment being investigated is expected to make or the size of difference that patients and clinicians would consider important. This is otherwise known as the target difference.

Although there are various methods in use to set this target difference, it turns out that not all of them are a good idea. The DELTA2 guidance stresses that the target difference should be both realistic – something that a trial can plausibly see – and important – a difference that patients and clinicians alike consider enough to change clinical practice.

"Getting the target difference and sample size is a critical part of designing a clinical trial," says Associate Prof Cook.

"Recruit too few people, and the study may not be able to draw firm conclusions about whether the new treatment actually works. Recruit more people than are actually needed, and those extra participants are needlessly involved in your trial, wasting their time, preventing them from enrolling in another study, and possibly spending valuable resource for no added information."

The guidance also helps researchers to clearly explain how their sample size was decided on. Funders reviewing grant applications and other researchers reading a study's protocol or results paper will then have enough information to understand and replicate the decisions, which is crucial for judging the trial's results themselves.

In a commentary piece published by Trials, Professor Melanie Bell of the University of Arizona highlights the potential benefit of this work: "The DELTA2 guidance will help to reduce the guesswork, and this should translate into better health research."

To reach as many researchers as possible, the DELTA2 guidance has been published simultaneously in the BMJ and BMC's Trials, with an accompanying blog post by the authors on the BioMed Central Blog Network. Trials has also created an article series on this key topic.

"My hope is that the DELTA2 guidance will provide the practical help for researchers that I wish I had had when I started out as a statistician working on clinical trials carrying out sample size calculations," says Associate Prof Cook. "Ideally funders and journals will recommend the guidance to the researchers they work with."

The DELTA2 project was funded by the Medical Research Council (MRC)/National Institute for Health Research (NIHR) UK Methodology Research Panel in response to an open commissioned call for an Effect Size Methodology State-of-the-art Workshop. The guidance was produced by a team of researchers from the UK, USA, and Canada.

Read the blog post

Similar stories

Oxford researchers call for an urgent re-evaluation of “weak” opioid safety profile

A new study associates dispensation doses of tramadol with increased risk of mortality, cardiovascular events, and fractures compared to the use of codeine to treat pain.

New therapeutic targets identified to treat inflammatory bowel disease

Millions of patients with ulcerative colitis or Crohn’s disease, collectively known as inflammatory bowel disease (IBD), are given fresh hope as a new study shows why some of them do not respond to current treatments.

Afsie Sabokbar wins Lifetime Achievement at Teaching Excellence Awards

Director of Graduate Studies Afsie Sabokbar wins Lifetime Achievement at 2021 Teaching Excellence Awards.

NDORMS staff recognised in the 2021 Teaching Excellence Awards

Director of Graduate Studies Afsie Sabokbar, Associate Professor Stephanie Dakin and Graduate Studies Officer Samuel Burnell were all winners in the Teaching Excellence Awards.

Five ways to take action for your bone health

On World Osteoporosis Day, the International Osteoporosis Foundation (IOF), the world’s largest non-governmental organisation in the bone field, urges action for osteoporosis and fracture prevention.

NDORMS researchers awarded funding by The Paget’s Association

Professor Philippa Hulley and Doctor Helen Knowles have been awarded funding by The Paget’s Association for their research on bone cells.